Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc. v. Capital Royalty Partners II, L.P., Capital Royalty Partners II - Parallel Fund “Aâ€, L.P., Parallel Investment Opportunities Partners, II, L.P., Capital Royalty Partners II (Cayman) L.P., CR Group, L.P., CRG Servicing, LLC, and Capital Royalty Partners II – Parallel Fund “B†(Cayman) L.P. Appeal from 151st District Court of Harris County (memorandum opinion per curiam)
Annotate this Case
Download PDF
Motion Granted; Appeal Dismissed and Memorandum Opinion filed December 28, 2023 In The Fourteenth Court of Appeals NO. 14-22-00882-CV NAVIDEA BIOPHARMACEUTICALS, INC. AND MACROPHAGE THERAPEUTICS, INC., Appellants V. CAPITAL ROYALTY PARTNERS II, L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND “A”, L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS, II, L.P.; CAPITAL ROYALTY PARTNERS II (CAYMAN) L.P.; CR GROUP, L.P.; CRG SERVICING, LLC; AND CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “B” (CAYMAN) L.P., Appellees On Appeal from the 151st District Court Harris County, Texas Trial Court Cause No. 2018-24442 MEMORANDUM OPINION This is an appeal from a judgment signed September 1, 2022. On December 6, 2023, appellants filed an agreed motion to dismiss the appeal. See Tex. R. App. P. 42.1. The motion is granted. Costs are taxed against the party incurring such costs. We dismiss the appeal. PER CURIAM Panel consists of Justices Bourliot, Zimmerer and Spain. 2
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
